Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH

 April 2, 2026

Pharmaceutical Technology

New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.

Clinical DataCardiovascularRead full story

Post navigation

Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling →
← Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com